Aldosterone in Diabetic Kidney Disease: From Mineralocorticoid Receptor Antagonism to Aldosterone Synthase Inhibition
Open Access
- 23 June 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5664
Abstract
Diabetic kidney disease (DKD) represents the single most common etiology of chronic kidney disease and end stage kidney disease globally, a burden that continues to expand in direct proportion to the worldwide growth of the diabetes epidemic. The pathogenesis of DKD is multifactorial, involving metabolic, hemodynamic, inflammatory, and fibrotic pathways. Among these, aldosterone has emerged as a key mediator of kidney injury, extending beyond its traditional role in sodium balance and blood pressure regulation. Through activation of both MR-dependent transcriptional processes and MR-independent signaling cascades, aldosterone drives a coordinated pattern of renal injury encompassing oxidative stress generation, endothelial dysfunction, podocyte damage, inflammatory cell recruitment, and progressive interstitial fibrosis. Current therapies targeting the renin–angiotensin–aldosterone system (RAAS), including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists, have significantly improved outcomes in DKD. Despite these advances, a considerable degree of residual cardiovascular and renal risk persists, attributable in part to the incomplete attenuation of aldosterone activity and the well-characterized phenomenon of aldosterone escape under sustained RAAS blockade. Aldosterone synthase inhibitors (ASIs) represent a mechanistically distinct therapeutic approach that targets aldosterone overproduction at its enzymatic source, potentially addressing both MR-dependent and independent pathways. Early clinical trials evaluating the efficacy of ASIs have demonstrated promising effects on blood pressure and albuminuria. This review summarizes the role of aldosterone in DKD pathogenesis, evaluates current therapeutic approaches, and discusses emerging evidence supporting ASIs as a potential addition to the evolving treatment landscape.Keywords
This publication has 43 references indexed in Scilit:
- Second-Generation Aldosterone Synthase Inhibitors for HypertensionJACC: Advances, 2026
- Aldosterone: Renal Action and Physiological EffectsComprehensive Physiology, 2023
- Interleukin-6 plays a critical role in aldosterone-induced macrophage recruitment and infiltration in the myocardiumBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
- High glucose stimulates expression of aldosterone synthase (CYP11B2) and secretion of aldosterone in human adrenal cellsFEBS Open Bio, 2017
- Podocyte injury and its consequencesKidney International, 2016
- Protein kinase D1 modulates aldosterone-induced ENaC activity in a renal cortical collecting duct cell lineMolecular and Cellular Endocrinology, 2010
- New aspects of rapid aldosterone signalingMolecular and Cellular Endocrinology, 2009
- Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular systemSteroids, 2005
- Rapid activation of Na + /H + -exchange in MDCK cells by aldosterone involves MAP-kinases ERK 1/2Pflügers Archiv - European Journal of Physiology, 2001
- Connective Tissue Growth Factor: What's in a Name?Molecular Genetics and Metabolism, 2000